Generic Priority Review Expanded In Senate User Fee Bill
Amendment added during markup would require eight-month review of ANDAs for shortage drugs and those with limited competition, as well as pre-submission meetings.
You may also be interested in...
User Fee Bill Caught In Comey Firing Tidal Wave
Senate committee forced to postpone mark-up of FDA user fee reauthorization legislation; drug pricing fight may be postponed by hearing pledge.
User Fee Add-Ons: Senate Bill Tweaks Orphans, Opioids, Patient Data
Manager's amendment tells US FDA to issue more guidance for complex generics and tells GAO to report on progress towards global harmonization of data standards.
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Legislation would create a potential second priority review pathway for generics, as well as another priority review voucher program, but may not be as enticing as GDUFA II proposal.